High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902 Journal Article
| Authors: | Stone, R. M.; Moser, B.; Sanford, B.; Schulman, P.; Kolitz, J. E.; Allen, S.; Stock, W.; Galinsky, I.; Vij, R.; Marcucci, G.; Hurd, D.; Larson, R. A. |
| Article Title: | High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902 |
| Abstract: | Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m2 over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m2 on day 7 and 4.5mg/m2 on day 14 was not tolerated, but HiDAC followed by GO 9mg/m2 on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy. © 2010 Elsevier Ltd. |
| Keywords: | adult; clinical article; treatment outcome; aged; middle aged; survival rate; acute granulocytic leukemia; overall survival; case-control studies; leukemia, myeloid, acute; drug tolerability; fatigue; neutropenia; drug efficacy; drug safety; side effect; treatment duration; cytarabine; drug megadose; outcome assessment; infection; phase 2 clinical trial; cohort studies; neoplasm recurrence, local; bleeding; nausea; stomatitis; thrombocytopenia; antineoplastic combined chemotherapy protocols; cohort analysis; relapse; dose-response relationship, drug; drug resistance, neoplasm; aminotransferase blood level; drug fever; drug hypersensitivity; dyspnea; febrile neutropenia; hypoxia; lung embolism; drug fatality; hypoalbuminemia; hypotension; antibodies, monoclonal; drug response; remission induction; hyperbilirubinemia; phase 1 clinical trial; idarubicin; anthracycline derivative; leukemia relapse; gemtuzumab ozogamicin; leukemia remission; liver venoocclusive disease; aminoglycosides; acute myeloid leukemia |
| Journal Title: | Leukemia Research |
| Volume: | 35 |
| Issue: | 3 |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2011-03-01 |
| Start Page: | 329 |
| End Page: | 333 |
| Language: | English |
| DOI: | 10.1016/j.leukres.2010.07.017 |
| PUBMED: | 20688393 |
| PROVIDER: | scopus |
| PMCID: | PMC3023007 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 23 June 2011" - "CODEN: LERED" - "Source: Scopus" |
